27
Additional paid-in capital 59,201 58,984
Other comprehensive income 28 86
Deficit accumulated during the
development stage (39,370) (35,492)
Total shareholders' equity 19,886 23,605
Total liabilities and shareholders'
equity $ 22,594 $ 26,038
ROSETTA GENOMICS LTD. AND ITS SUBSIDIARY
(A development stage company)
CONSOLIDATED STATEMENTS OF OPERATIONS
U.S. dollars in thousands (except share and per share data)
Three months
Year ended December 31, ended March 31,
2007 2006 2008 2007
Unaudited
Operating expenses:
Research and development, net $ 6,400 $ 4,781 $ 2,389 $ 1,161
Marketing and business
development 1,742 1,504 511 375
General and administrative 2,903 1,860 829 680
Operating loss 11,045 8,145 3,729 2,216
Financial expenses (income),
net 3,616 (538) 149 (200)
Net loss $ 14,661 $ 7,607 $ 3,878 $ 2,016
Basic and diluted net loss
per Ordinary share $ 1.32 $ 2.98 $ 0.33 $ 0.23
Weighted average number of
Ordinary shares used to
compute basic and diluted
net loss per Ordinary share 11,142,149 2,551,860 11,920,401 8,874,841
Contact: Media
Rachel Spielman
T: +1-212-583-2714
E:
SOURCE Rosetta Genomics Ltd Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Related biology technology :1.
Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 20072.
NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma3.
Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference4.
Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference5.
Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 20076.
Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 20077.
Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer8.
Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology9.
Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma10.
Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 200811.
Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer